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Structured Abstract 
Background 
The incidence of clinically apparent stroke in transcatheter aortic valve implantation 
(TAVI) exceeds that of any other procedure performed by interventional cardiologists 
and, in the index admission, occurs more than twice as frequently with TAVI than 
with surgical aortic valve replacement (SAVR). However, this represents only a hint 
of the vast burden of neurological injury that occurs during TAVI, with recent 
evidence suggesting that many strokes are clinically silent or only subtly apparent. 
Additionally, such injury may present with subtle neurocognitive dysfunction rather 
than overt neurological deficits. The underlying insult behind all types of injury 
remains poorly characterized. 
 
Methods  
The Silent and Apparent Neurological Injury in TAVI (SANITY) Study is a 
prospective, multicenter, observational study comparing the incidence of neurological 
injury after TAVI versus SAVR. It introduces an intensive, standardized, formal 
neurologic and neurocognitive disease assessment for all aortic valve recipients, 
regardless of intervention (SAVR vs. TAVI), valve-type (bioprosthetic, Edwards 
SAPIEN-XT or Medtronic CoreValve) or access route (sternotomy, transfemoral, 
transapical or transaortic). It also provides the most comprehensive monitoring of 
embolic insults than can be found in current literature, to more fully define the burden 
of neurological disease.  
 
Conclusion 
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The SANITY study undertakes the most rigorous assessment of neurological injury 
reported in literature to date. It attempts to accurately characterize the insult and 
sustained injury associated with both TAVI and SAVR in an attempt to advance 
understanding of this complication and associations thus allowing for improved 
patient selection and procedural modification.  
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Background 
Emerging data now supports TAVI  as an acceptable strategy in the management of 
severe aortic stenosis (AS) amongst patients deemed ineligible or too high-risk for 
SAVR. Despite the technique’s success, the risk of neurological insult and injury 
associated with TAVI has raised concerns. This injury may take the form of either 
cerebrovascular events (CVEs) - including major/disabling stroke, minor/non-
disabling stroke, transient ischemic attacks (TIAs) or silent brain infarcts; or 
neurocognitive dysfunction - especially post-operative cognitive dysfunction (POCD) 
or post-operative delirium (POD). Such events may be overt, subtle, or clinically 
silent. While overt stroke rates have been reported in most safety and efficacy 
studies/registries, subtle and silent neurological injuries have been either unreliably 
recorded or, more often, largely ignored because of prevailing clinical approaches. 
Additionally, although emboli are thought to be the major cause, especially of early 
neurological injury, the underlying insults behind both types of injury remain poorly 
characterized.  
 
Clinically apparent Cerebrovascular Events 
CVEs are more common post TAVI than after alternative management strategies, 
with rates amongst the highest reported for any cardiac procedure. CVEs post 
cardiovascular interventions vary in their presentation and timing, allowing for 
distinction of etiologies and risk factors (Table 1).  
 
Thirty-day stroke rates of 3.3%, 2.4% and 1-2% have been reported for risk-matched 
populations undergoing TAVI, isolated AVR, and balloon valvuloplasty, 
respectively[1-3]. For all three interventions, this risk is highest within the first 24 
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hours, suggesting an early hazard phase immediately post-procedure[4]. It is this early 
hazard phase that is considered ‘procedurally-related’ and represents the period 
during which TAVI recipients are at increased risk. Improved understanding of events 
during this period therefore promises the greatest potential for optimization of TAVI 
and as such is the focus of the SANITY Study.  
 
Silent Brain Infarction 
In neuroimaging studies, clinically apparent strokes account for only a minority of 
CVEs. Diffusion-weighted magnetic resonance imaging (DWI) studies have revealed 
the incidence of new ischemic lesions as approximately 75% post-TAVI, and as high 
as 93% [5, 6]. Comparatively, only 40-50% are evident in DWI studies following 
SAVR, and 22% following retrograde catheterization of the aortic valve in AS[5, 7]. 
Understanding of these clinically silent CVEs is more limited than for clinically 
apparent strokes, with only a few published MRI-centered studies investigating their 
occurrence post-TAVI, amounting to fewer than 200 patients. The clinical relevance 
of this burden of infarct remains unknown, though has been suggested to correlate 
with increased risk of post-operative cognitive dysfunction (POCD) or post-operative 
delirium (POD)[8, 9]. 
 
Neurocognitive Impairment 
Investigation into neurological injury post-TAVI has almost exclusively focused on 
CVEs, with neurocognitive/neuropsychological disturbances disregarded. This 
reflects both the uncertain consequences of such neurological injury and the difficulty 
of detecting these events. Two entities of particular interest are post-operative 
delirium (POD) and post-operative cognitive dysfunction (POCD), which are defined 
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in Table 1. Though clinical experience suggests that these are common entities post-
cardiovascular intervention and surgery, studies geared towards their detection are 
sparse and limited by insensitive screening tools.  
 
Neurological Insult: 
The underlying neurological insult resulting in injury is thought to be primarily an 
embolic phenomenon, though inter-related etiologic factors of hypoperfusion, 
thrombosis and hemorrhage are likely of importance. Transcranial Doppler (TCD) 
studies have demonstrated micro-emboli at all stages of the TAVI procedure, with 
cumulative embolic loads exceeding 700 high-intensity signals (HITS, a validated 
surrogate of emboli) reported, especially during stages of aortic valve 
manipulation/TAVI deployment. However, the TCD data used to quantify and 
characterize the embolic etiology is based on a limited number of small studies. 
Importantly, no studies to date have compared the degree of neurological insult 
detected by TCD and MRI within the same cohort of patients.   
 
Area of need 
Clearly, across all forms of neurological injury, current understanding of the nature 
and character of both the injury and the underlying insult is incomplete. This is the 
consequence of studies not being specifically geared towards sensitive neurological 
insult/injury detection. The paucity of data reflects the relative ignorance of this 
complication in the face of the significant functional benefits to patients who are 
ineligible or at high-risk for SAVR. Refinement of TAVI continues with the 
expectation that complications can and should be minimized. Indeed, the greatest 
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barrier to TAVI extending into lower surgical risk and younger populations remain 
the risk of neurological injury.  
 
Objectives 
The SANITY study (ACTRN12613000083796) aims to provide the most 
comprehensive characterization to date of neurological insult and injury - both 
clinically apparent and silent - post TAVI and SAVR. Specific primary and secondary 
objectives are outlined in Table 2. These encompass pre-existing patient factors, and 
both intra- and post-operative factors thought to influence neurological insults and 
injury sustained during aortic valve interventions. It is hoped that improved 
understanding of these associations will permit detailed characterization of 
neurological injury during TAVI and allow for the identification of predictors of such 
injury. 
 
Hypotheses 
Based on the current concept of neurological injury and extrapolation of procedural 
risk factors for embolization, it is hypothesized that neurological insult is less 
pronounced with: 
1. AVR than TAVI. This may be due to removal of the valvular source of 
embolization, which in TAVI persists, pushed against the wall of the aorta and 
potentially acting as a nidus for calcific emboli and altered rheology, 
promoting thrombosis.  
2. A transapical/transaortic than transfemoral approach. Transapical/ transaortic 
routes avoid the risk of disrupting calcific plaques especially in the aortic arch, 
an inherent risk with femoral access. 
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3. The Edwards SAPIEN versus Medtronic CoreValve. The CoreValve system is 
associated with relatively slower stepwise release and repositioning, which is 
postulated to ‘grate’ calcific debris off the stenotic valve.  
 
Methods 
Study Design 
This is a prospective, multicenter, non-random observational study comparing the 
incidence of neurological injury associated with transcatheter aortic valve 
implantation (TAVI) versus surgical aortic valve replacement (SAVR). 
 
Regularly held ‘Heart Team’ meetings - comprised of multiple disciplines including 
echocardiologists, interventional cardiologists, nurses and cardiothoracic surgeons – 
will assess high-risk patients with severe AS. Here, patients will be allocated to the 
intervention clinically indicated. Pending consent, such patients will be consecutively 
recruited into the SANITY study, resulting in cohort grouping as outlined in Figure 1.  
 
Patient Population 
Thorough pre-, intra- and post-procedural assessments allow for results to be adjusted 
for baseline status, thus permitting an inclusive approach to enrollment. As such, only 
patients unable to participate in aspects of assessment (Table 3) will be excluded. 
Patients will then be grouped, as outlined above, for comparison.  
 
Data Collection 
The complete assessment regime and timing of each component can be found in 
Figure 2. Where relevant, this regime was designed to be consistent with the 
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assessments recommended and satisfy the endpoints defined by the Valve Academic 
Research Consortium updated standardized endpoints (VARC-2)[10]. A multi-
disciplinary approach has been adopted to ensure that relevant experts address each 
assessment domain. 
 
Medical/Medication History 
Qualified medical or nursing personnel will administer a detailed, standardized 
questionnaire, either at the time of consent or, in cases of telephone consent, at first 
subsequent contact. This is aimed at identifying all pre-existing cerebrovascular and 
neurocognitive risk factors and assigning formal surgical-risk scores using the Society 
for Thoracic Surgeons (STS) scale and European System for Cardiac Operative Risk 
Evaluation (EuroSCORE) I and II. At each contact specific questioning and chart 
review will target transient ischemic events that might otherwise be missed using the 
neurological assessment protocol outlined below.   
  
Neurological and Cognitive Assessment 
There are no standards or recommendations guiding neurocognitive assessment in the 
TAVI population. It is clear that post-TAVI, the mini-mental state exam (MMSE) 
yields little information and is susceptible to a ‘learning effect’[6]. More recently, the 
Montreal Cognitive Assessment (MoCA) has emerged as a useful cognitive screening 
test and generally is considered more sensitive for vascular cognitive impairment due 
to the inclusion of a thorough executive function assessment[11]. Additionally, the 
Confusion Assessment Method (CAM) will be performed. This is the standard 
screening tool used in the detection of delirium in the postoperative period however, 
has not been validated in a post-cardiac intervention population against the ‘gold-
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standard’ of a consultant psychiatrist/geriatrician clinical assessment[12]. These three 
tools (MoCA, CAM, consulting geriatrician’s assessment) will comprise the cognitive 
assessment for the SANITY study, providing clinically important information on the 
incidence and pattern of cognitive impairment in this population, and potentially 
validating the instruments themselves in the post-cardiac intervention/surgery 
population. Tests will be performed prior to the index procedure (to provide a 
baseline) and at days 1,4 and 7 and at 6 weeks and 3 months post-index procedure. 
 
Clinical Neurological Assessment  
The NIH Stroke Scale (NIHSS) is a widely validated tool, which facilitates the 
standardized objective quantification of impairment caused by stroke. Categorization 
of stroke severity (no stroke, minor stroke, moderate stroke, moderate to severe stroke 
and severe stroke) is permitted, based on the overall score. Where stroke is identified 
(pre-existing or new), the modified Rankin Scale (mRS) will be applied to measure 
and monitor stroke-related disability. These assessments will be applied at the same 
time points as outlined for the cognitive assessment tools.  
 
Serological Assessments 
Numerous serological markers of neurological injury that have been utilized 
previously in acute ischemic stroke (AIS) Most of these have not been studied to any 
great extent in patients undergoing cardiovascular interventions; thus, the ideal 
marker in this setting is unknown. Following careful consideration of strengths and 
weaknesses of each (Table 4), GFAP and S100B were selected for use in the SANITY 
study.  The time points for testing will be pre-procedure and 24hrs, 48hrs, 72hrs and 
96hrs post-procedure. 
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Imaging Assessments  
Echocardiography: 
Echocardiography either transoesophageal or transthoracic will be performed on all 
patients prior to and following the aortic valve procedure for the purposes of grading 
aortic stenosis. Additionally, evidence for intra-cardiac thrombi and spontaneous echo 
contrast will be sought. Increased presence of both of these parameters has been 
identified in TAVI patients, likely as a result of an acquired thrombophilic state [13].  
 
Transcranial Doppler (TCD)  
TCD uses Doppler ultrasonography transduced through established windows in the 
skull (areas of bone thinning) to detect and quantify emboli (high-intensity signals 
and micro-embolic signals) using defined criteria[14]. Additionally, cerebral blood 
flow can be measured and assessed with respect to changes in systemic pressure to 
determine cerebral autoregulation. These measures will be performed intra-
operatively allowing for temporal analysis with relation to stage of procedure.  
 
Carotid Duplex Ultrasound 
The association between carotid stenosis and postoperative stroke following 
cardiovascular interventions remains controversial. It is feasible that CAS may play a 
role, albeit currently undefined, and may be a predictor of stroke in TAVI[15]. As 
such, carotid duplex ultrasound will be performed on all patients at baseline to 
identify CAS within the common, internal and external carotid arteries. Stenosis and 
plaque burden will be graded, taking into consideration all information from B-mode, 
pulsed-wave and color-flow Doppler.  
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CT Chest/Vascular Calcification Score 
Arterial calcification correlates with atherosclerotic plaque burden[16]. The Agatston 
Score Equivalent (ASE) is a widely used method of quantifying the calcified plaque 
burden in coronary arteries using non contrast CT[17].  Thus, a low dose, non contrast 
acquisition will form part of the standard CT angiographic assessment of the aorta and 
the iliofemoral access arteries as routinely performed for TAVI suitability assessment 
and planning. ASEs of the aorta can be calculated for each of the aortic vessel 
segments, including the aortic root and valve leaflets. The correlation between the 
vascular and aortic valve plaque burden and neurological insult can thus be 
determined. 
 
Magnetic Resonance Imaging (MRI) 
Recognized as the most sensitive technique for the detection of acute ischemic 
cerebral infarcts, DWI detects the restriction of water diffusion in cerebral tissue 
caused by hypoxic oedema within minutes of ischemia onset. Increased signal 
intensity on DWI is reliably detectable 4 hours post insult and persists for up to 10 
days[18]. Lesions representing brain infarct can be quantified in number and size and 
volume using this modality.  
 
Susceptibility Weighted Imaging (SWI) is a relatively new MRI sequence which is 
highly sensitive to the local magnetic field inhomogeneity caused by paramagnetic 
substances including the heme group in hemoglobin. SWI is commonly used as an 
adjunct to DWI in the assessment of cerebral ischaemia as it is extremely sensitive for 
detecting hemorrhagic transformation within regions of infarction; can demonstrate 
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acute thrombo-emboli sufficient to occlude arteries and can detect micro-hemorrhage, 
suspected to originate from diapedesis of red blood cells across overtly permeable 
capillaries. Peak incidence of hemorrhagic transformation occurs between 48 hrs and 
5 days and can persist for years[18].  
 
Patients will undergo a baseline MRI study one week prior to intervention. This more 
comprehensive study will include standard fast spin echo sequences, baseline DWI 
and SWI sequences and time of flight angiography of the circle of Willis to document 
pre-existing disease. At 4 days post intervention a limited study consisting of DWI, 
SWI, T2 Flair and T1 imaging will be performed. The 4-day interval length allows for 
sufficient patient recovery post procedure to safely undergo an MRI examination and 
allows for establishment of the MRI detectable changes and maximum evolution of 
the ischemic change[19]. This limited acquisition is performed in 15 min for 
increased patient tolerance. A further limited examination after 6 weeks will include 
DWI and SWI, demonstrating DWI resolution, infarct complications and finally 
accounting for all SWI lesions. 
 
Monitoring 
Cerebral Oxygen Saturation (rSO2): 
Transcranial cerebral oximetry non-invasively monitors cerebral oxygen saturation in 
the frontal lobes of the brain and has been shown to correlate with cerebral venous 
oxygen saturation, which is traditionally considered the ‘gold-standard’ for 
determining oxygen delivery/consumption[20]. It has been used in a limited number 
of studies to monitor the cerebral oxygen delivery compromise associated with rapid 
ventricular pacing[21, 22]. This will be applied during the intra-operative period. 
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Invasive Blood Pressure 
Hemodynamic instability leading to systemic hypotension may impair cerebral 
perfusion pressure beyond auto-regulatory capacity, resulting in hypoperfusion[23]. 
While itself a cause of ischaemia, low cerebral flow magnifies the effects of micro-
emboli by impairing their clearance and permitting small emboli to lodge[24]. 
 
Telemetry: 
Intra- and post-operative telemetry will be employed to measure the duration of rapid 
ventricular pacing and detect new onset atrial fibrillation (NOAF). NOAF complicates 
14–32% of TAVI procedures and episodes as brief as 30 seconds have been 
associated with up to a three-fold increased risk of CVE’s [25]. Patients will be 
monitored on telemetry during and for a minimum of 3 days following the index 
procedure. 
 
Quality of Life 
Quality of life (QoL) assessment during post-procedural follow-up is crucial to 
determining the clinical benefit of TAVI and consequences of neurological and 
cognitive insult and injury. Recommendations of the VARC-2 necessitate both a 
health-specific measure and generalized measure of QoL [26]. As such, the heart 
failure specific Kansas City Cardiomyopathy Questionnaire (KCCQ) [27], and the 
generic European Quality of Life instrument-5D (EQ-5D) [28] have been selected. 
These will be performed prior to and 3 months following index procedure.  
 
Frailty and Functional Outcome Measures: 
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Functional capacity will be measured objectively by the six-minute walk test 
(6MWT), conducted according to American Thoracic Society guidelines [29]. This 
simple, practical and inexpensive sub-maximal exercise test assesses functional 
capacity [30], is closely linked to activities of daily living and has been proposed as 
both a functional status indicator and an outcome measure [31]. Similarly, gait speed 
is an important indicator of frailty [32], with slow gait a strong predictor of adverse 
outcomes, including disability, high healthcare utilization and mortality [33].  
 
Frailty can be described as a vulnerability to adverse events that is associated with, 
but separate from chronological age[34]. Implicitly, all patients requiring TAVI as 
opposed to open aortic valve surgery must have frailty as a barrier to standard 
treatment. Frailty is therefore an important contributor to the choice of TAVI and a 
potential confounder regarding outcomes, including delirium. Deficit accumulation 
provides a robust measure of frailty[35]. This measure improves understanding of 
what is happening to the frailest frail and those unable to complete performance-based 
tests. 
 
Endpoint Definitions 
The endpoints for the SANITY study are outlined in Figure 3. Primary endpoints 
focus on the characterization and quantification of the neurological insult, with 
specific reference to the embolic load, as detected by transcranial Doppler and new 
ischemic lesions on MRI. Secondary end points focus on the clinically apparent 
neurological injury sustained and markers of insult / injury. 
 
Statistical Analysis  
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An estimated 100 patients will be recruited into this study, fifty in each of the two 
treatment arms (SAVR and TAVI). Fifty patients per group yields 90% power to 
detect a difference in mean HITS of 500 in one group and 518 in another, assuming a 
standard deviation of 30 and a two-sided statistical significance of 5%. This is based 
upon estimates drawn from previous data on the quantification of embolic load during 
TAVI/AVR. Fifty patients per group also provides 90% power to detect differences in 
the incidence of new DWI lesions with two-sided statistical significance of 5%, 
assuming overall incidence estimates of 76% and 45% with TAVI and AVR, 
respectively, as previously reported.  
 
Multiple regression models will be used to adjust for potential confounders identified 
based upon clinical importance and statistical selection The key output will be the 
estimated treatment difference and 95% confidence intervals for the primary group 
from the multiple regression model. Additionally, longitudinal analysis will be used to 
examine all outcomes with repeated data again with application of multiple regression 
model. Treatment failure and withdrawal will be considered on an intention-to-treat 
basis, providing a more realistic estimate of the difference between groups in actual 
clinical practice.  
 
Limitations 
Across all TAVI literature the identification of a risk-matched control group has 
proven difficult. The validity of high-risk SAVR patients as a ‘control group’ has 
previously been questioned, given that level of health risk is a factor determining 
which procedure will be used. Comparison between these two groups however is 
more clinically relevant as AVR is the current ‘gold-standard’ for eligible patients 
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with AS. Additionally, by pooling data from the two treatment groups for multivariate 
analysis, it will be possible to assess whether pre-procedural general health is a 
significant predictor of insult / injury.  
 
This study will be non-randomized and non-blinded. Though multiple regression 
analysis will be used to minimize confounding, this is not a substitute for blinding or 
randomization, and unmeasured confounders may produce hidden bias.  
 
Finally, a clinical follow-up duration of three months limits conclusions regarding 
delayed and late neurological injury. Such a timeframe can be justified, however, 
given that DWI findings resolve within this timeframe (usually quoted as occurring 
by 30 days even in overt stroke) and reversible neurocognitive deficits generally 
resolve by 3 months[9]. Consequently, the financial costs and patient burdens of 
prolonging follow-up cannot be ethically justified.  
 
Summary 
The SANITY Study offers the most comprehensive neurological/neurocognitive 
assessment of the high-risk TAVI and AVR patient population to date. Well-
established and recommended assessments are complemented by those that are novel 
and unique, thereby offering the potential of improved understanding of the 
interventions in question, correlation of risk factors and prognostic markers, and 
validation of assessment tools. Such knowledge is vital to establishing both suitable 
assessment batteries and guidelines in this unique, high-risk group of patients, and to 
advancing strategies for neurological injury reduction. 
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Appendices 
Table 1: Definitions used for the trial 
A. Cerebrovascular Event definitions[10]  
Diagnostic Criteria: 
Acute episode of a focal or global neurological deficit with at least one of 
the following: change in the level of consciousness, hemiplegia, 
hemiparesis, numbness, or sensory loss affecting one side of the body, 
dysphasia or aphasia, hemianopia, amaurosis fugax, or other neurological 
signs or symptoms consistent with stroke.  
A. Stroke 
Duration of a focal or global neurological deficit ≥ 24 hours; OR <24 hours 
if available neuroimaging documents a new hemorrhage or infarct; OR the 
neurological deficit results in death.  
Aetiology: 
i. Ischemic: an acute episode of focal cerebral, spinal or retinal 
dysfunction caused by infarction of the central nervous system 
tissue. 
ii. Hemorrhagic: an acute episode of focal or global cerebral or 
spinal dysfunction caused by intraparenchymal, intraventricular, or 
subarachnoid hemorrhage. 
iii. Undetermined: insufficient information to allow categorization as 
ischemic or hemorrhagic. 
Severity: 
i. Disabling stroke (Major): an mRS of 2 or more at 90 days and an 
increase in at least one mRS category from an individuals pre-
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stroke baseline. 
ii. Non-disabling stroke (Minor): an mRS score of <2 at 90 days or 
one that does not result in an increase in at least one mRS category 
from an individual’s pre-stroke baseline.  
B. TIA:  
Duration of a focal or global neurological deficit <24 hours, any available 
neuroimaging does not demonstrate a new hemorrhage or infarct. 
 
Qualifiers: 
 Exclusion of non-stroke causes for clinical presentation 
o e.g. brain tumour, trauma, infection, hypoglycemia, peripheral lesion, 
pharmacological influences etc.  
 Determined by or in conjunction with the designated internal medicine 
specialist or neurologist. 
 Diagnosis confirmed by at least one of the following: 
 Neuroimaging procedure (CT scan or MRI brain) and/or 
 Neurologist or neurosurgical specialist 
 
B. Neurocognitive Impairment 
A.  Post-operative Cognitive Dysfunction (POCD) 
Definition: Deterioration of intellectual function presenting as impaired 
memory or concentration presenting with temporal association to surgery. 
B. Post-operative Delirium (POD) 
Definition: An acute disturbance of consciousness and a change in cognition 
with tendency to fluctuate during the course of the day and occurring in 
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patients without some other identifiable aetiology and following normal 
emergence from anaesthesia. 
Qualifiers: 
 Determined by specialist geriatrician assessment 
 In conjunction with CAM and MoCA assessment tools 
 
Table 2: Objectives of the SANITY Study 
Primary Objectives: 
Characterize neurological insult (Transcranial Doppler evidence of microemboli) and 
neurological injury (MRI evidence of new ischemic lesions) during the TAVI 
procedure compared with AVR 
Define the association between incidence of neurological insult and injury with: 
- Aortic Valve Intervention (TAVI, AVR) 
Secondary Objectives: 
Define the association between incidence of neurological insult and injury with: 
- TAVI access (transfemoral, transapical, transaortic) 
- TAVI prosthesis (Edwards SAPIEN, Medtronic CoreValve) 
Define the association between incidence of neurological insult and: 
- Clinically apparent neurological injury 
- New Onset Atrial Fibrillation 
- Neurocognitive dysfunction 
- Degree of vascular / aortic valve calcification 
- Rapid ventricular pacing and cerebral desaturation 
- Serological markers of neurological injury (S100B and GFAP) 
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- Cerebrovascular reserve 
- Effect on cerebral blood flow 
Validate: 
- GFAP as a serological marker of neurological injury in cardiovascular 
intervention 
- Neurocognitive screening tools in cardiothoracic intervention 
 
Table 3: Eligibility Criteria 
Inclusion Criteria Exclusion Criteria 
Informed consent for participation Lacks capacity to consent for him or 
herself 
Severe Aortic Stenosis 
- AVA <0.8cm2 
- Mean Aortic Valve Gradient 
>40mmHg 
- Peak jet velocity >4m/s 
Pre-existing neurological impairment 
- Modified Rankin score ≥ 3 (i.e. 
Moderate disability; requiring 
some help, but able to walk 
without assistance) 
-  
Planned TAVI or AVR Contraindication to MRI (including 
incompatible metallic prosthesis/foreign 
body, inability to lie flat, claustrophobia 
requiring sedation) 
EuroScore >20 or STS-PROM >10  Non or poor English-speaking due to 
nature of and unknown validity in such 
populations cognitive testing 
 Previous Aortic Valve Repair / 
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replacement 
 Coronary artery disease requiring 
revascularisation (including patients 
undergoing combined AVR and CABG) 
 SANITY Study Investigational Protocol V3.0 26 
 
Table 4: A comparison of Serological Markers of Neurological Injury 
      Used in 
Test Function/Rational for Use Strengths & Weaknesses 
SANITY 
Study 
CK-BB Involved in energy metabolism Levels do not correlate with stroke severity NO 
  of neural cells     
        
Neuron-specfic 
enolase A glycolytic enzyme involved in Levels increase after acute brain injury NO 
(NSE) anaerobic metabolism of glucose Non-specific; levels increase after ANY injury   
    After acute stroke, levels do not correlate with function   
        
        
Neurofilaments Proteins integrated into neuronal Relationship to infarct size & functional outcome unclear NO 
(NfH) & axonal cytoskeleton     
        
Tau Microtubule-associated protein Poor sensitivity for stroke; only high in 27-48% of patients NO 
  stabilizes axonal cytoskeleton     
  & transport of vesicles to synapse     
        
S100 proteins Calcium-binding proteins involved Best established marker of acute brain ischemia YES 
  various cellular processes Levels correlate with infarct size, clinical severity &   
    functional outcome   
    
Presence in non-neural tissues like adipocytes, 
chondrocytes    
    & melanocytes reduce specificity   
        
GFAP Intermediate filament in astroglial Levels correlate with infarct size, clinical severity & YES 
  cytoskeleton; involved in repair of functional outcome   
  neural tissue after injury Subtypes exist specific to different tissues, which enhances   
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    specificity   
    However, not yet validated in cardiac intervention patients   
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Figure 1: SANITY Study Design 
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Figure 2: Overview of SANITY Assessments 
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Figure 3: Overview of SANITY Variables and Endpoints 
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